This webinar discusses how the Estonian Biobank, a cohort of more than 165,000 participants, is addressing industry challenges with data management and collaboration in the transition to precision medicine.
The explosion of big data, together with rapidly developing technology, holds untapped potential for drug discovery and personalized healthcare studies. Accordingly, biobanks are emerging as an essential tool for discovery and clinical development, with their extensive datasets originating from diverse profiles of individuals and populations. However, the full power of this data is yet to be unlocked, due to both industry and academia grappling with challenges in managing, harmonizing, and integrating data and resources.
The following webinar discusses the ways to address and potentially solve such industry challenges, with insights from the Vice-Director of the Estonian Genome Center, Tonu Esko. The Estonian Biobank is one of the world’s leading resources for developing precision medicine applications, with its forward-looking laws, longitudinal digital health repositories, and availability of biological samples. Their work aims to promote the development of human genetics research, collecting information on health issues and genetics of the Estonian population, and implement genomic data in medical practice, with the aim to improve population health.
The discussion highlights the Estonian Biobank’s experience supporting precision medicine and operating as a data partner in BC Platforms’ global network, a secure environment for data reservoirs to display their data collections, while maintaining ownership and security, for pharmaceutical researchers who seek diverse patient cohorts for clinical research and drug development projects.